Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX

Founder-led company

Crinetics Pharmaceuticals stock price today

$30.24
-21.61
-41.68%
Financial Health
0
1
2
3
4
5
6
7
8
9

Crinetics Pharmaceuticals stock price monthly change

-3.39%
month

Crinetics Pharmaceuticals stock price quarterly change

-3.39%
quarter

Crinetics Pharmaceuticals stock price yearly change

+42.52%
year

Crinetics Pharmaceuticals key metrics

Market Cap
4.90B
Enterprise value
N/A
P/E
-5.05
EV/Sales
-6.29
EV/EBITDA
0.18
Price/Sales
0.17
Price/Book
N/A
PEG ratio
0.40
EPS
-3.78
Revenue
N/A
EBITDA
-247.78M
Income
-235.46M
Revenue Q/Q
-76.11%
Revenue Y/Y
-53.93%
Profit margin
-3460.38%
Oper. margin
-3544.06%
Gross margin
0%
EBIT margin
-3544.06%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Crinetics Pharmaceuticals stock price history

Crinetics Pharmaceuticals stock forecast

Crinetics Pharmaceuticals financial statements

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Profit margin
Jun 2023 988K -50.97M -5159.82%
Sep 2023 346K -57.45M -16606.36%
Dec 2023 0 -60.09M
Mar 2024 640K -66.93M -10457.81%
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Analyst Estimates
Sep 2025 9.36M -66.47M -709.57%
Oct 2025 910.6K -75.75M -8319.67%
Dec 2025 4.57M -76.48M -1672.76%
Mar 2026 5M -76.62M -1532.53%
  • Analysts Price target

  • Financials & Ratios estimates

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Debt to assets
Jun 2023 293254000 39.13M 13.35%
Sep 2023 641537000 93.78M 14.62%
Dec 2023 635353000 96.24M 15.15%
Mar 2024 978153000 103.22M 10.55%
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Cash Flow
Jun 2023 -45.73M 31.43M 12.65M
Sep 2023 -41.33M -193.29M 337.87M
Dec 2023 -38.51M -87.30M 37.92M
Mar 2024 -52.85M 309K 393.57M

Crinetics Pharmaceuticals alternative data

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Employee count
Aug 2023 210
Sep 2023 210
Oct 2023 210
Nov 2023 210
Dec 2023 210
Jan 2024 210
Feb 2024 210
Mar 2024 290
Apr 2024 290
May 2024 290
Jun 2024 290
Jul 2024 290

Crinetics Pharmaceuticals other data

29.94% -70.06%
of CRNX is owned by hedge funds
15.56M -39.32M
shares is hold by hedge funds

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 30375
Mar 2024 0 119390
Apr 2024 0 55326
May 2024 0 113448
Jun 2024 0 63585
Jul 2024 0 106431
Aug 2024 0 6000
Sep 2024 0 26035
Oct 2024 0 14375
Nov 2024 0 501
Dec 2024 0 10000
Transaction Date Insider Security Shares Price per share Total value Source
Option
BETZ STEPHEN F. officer: Chief Scientific Officer
Stock Option (Right to Buy) 2,331 $1.91 $4,452
Option
BETZ STEPHEN F. officer: Chief Scientific Officer
Common Stock 2,331 $1.91 $4,452
Sale
STRUTHERS RICHARD SCOTT director, officer: President & ..
Common Stock 10,000 $57.57 $575,700
Sale
KNIGHT JEFF E. officer: Chief Operating Officer
Common Stock 501 $56.52 $28,317
Option
PIZZUTI DANA officer: Chief Med and Dev Offi..
Stock option (Right to Buy) 14,375 $16.89 $242,794
Option
PIZZUTI DANA officer: Chief Med and Dev Offi..
Common Stock 14,375 $16.89 $242,794
Sale
PIZZUTI DANA officer: Chief Med and Dev Offi..
Common Stock 14,375 $54.63 $785,306
Option
WILSON MARC officer: CFO Common Stock 25,000 $15.29 $382,250
Option
WILSON MARC officer: CFO Common Stock 25,000 $15.29 $382,250
Sale
WILSON MARC officer: CFO Common Stock 25,000 $51.11 $1,277,750
Patent
Application
Filling date: 15 Jul 2020 Issue date: 25 Aug 2022
Application
Filling date: 16 Feb 2022 Issue date: 18 Aug 2022
Application
Filling date: 25 Jan 2022 Issue date: 12 May 2022
Application
Filling date: 21 Jan 2022 Issue date: 12 May 2022
Application
Filling date: 7 Sep 2021 Issue date: 10 Mar 2022
Grant
Filling date: 7 Sep 2021 Issue date: 8 Mar 2022
Application
Filling date: 26 Oct 2021 Issue date: 17 Feb 2022
Grant
Filling date: 19 May 2020 Issue date: 30 Nov 2021
Application
Filling date: 8 Feb 2021 Issue date: 5 Aug 2021
Grant
Filling date: 16 Sep 2019 Issue date: 27 Jul 2021
Insider Compensation
Dr. R. Scott Struthers (1962) Founder, Pres, Chief Executive Officer & Director
$820,330
Dr. Ajay Madan DABT, Ph.D., D.A.B.T. (1968) Chief Devel. Officer
$567,530
Mr. Marc J. C. Wilson (1979) Chief Financial Officer & Sec. $527,720
Tuesday, 10 December 2024
globenewswire.com
Monday, 9 December 2024
globenewswire.com
Thursday, 14 November 2024
globenewswire.com
Tuesday, 12 November 2024
seekingalpha.com
globenewswire.com
globenewswire.com
Monday, 11 November 2024
globenewswire.com
Thursday, 10 October 2024
globenewswire.com
Tuesday, 8 October 2024
globenewswire.com
globenewswire.com
Monday, 7 October 2024
finbold.com
Thursday, 26 September 2024
globenewswire.com
Tuesday, 10 September 2024
globenewswire.com
Thursday, 29 August 2024
globenewswire.com
Monday, 12 August 2024
globenewswire.com
Thursday, 8 August 2024
seekingalpha.com
zacks.com
globenewswire.com
Thursday, 1 August 2024
zacks.com
Thursday, 18 July 2024
globenewswire.com
Wednesday, 10 July 2024
globenewswire.com
Wednesday, 26 June 2024
investorplace.com
Tuesday, 18 June 2024
globenewswire.com
Monday, 10 June 2024
globenewswire.com
Monday, 3 June 2024
globenewswire.com
globenewswire.com
Thursday, 30 May 2024
globenewswire.com
Wednesday, 22 May 2024
globenewswire.com
Saturday, 11 May 2024
Seeking Alpha
Thursday, 9 May 2024
Zacks Investment Research
  • What's the price of Crinetics Pharmaceuticals stock today?

    One share of Crinetics Pharmaceuticals stock can currently be purchased for approximately $30.24.

  • When is Crinetics Pharmaceuticals's next earnings date?

    Unfortunately, Crinetics Pharmaceuticals's (CRNX) next earnings date is currently unknown.

  • Does Crinetics Pharmaceuticals pay dividends?

    No, Crinetics Pharmaceuticals does not pay dividends.

  • How much money does Crinetics Pharmaceuticals make?

    Crinetics Pharmaceuticals has a market capitalization of 4.90B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 15.28% to 4.01M US dollars.

  • What is Crinetics Pharmaceuticals's stock symbol?

    Crinetics Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "CRNX".

  • What is Crinetics Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Crinetics Pharmaceuticals?

    Shares of Crinetics Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Crinetics Pharmaceuticals's key executives?

    Crinetics Pharmaceuticals's management team includes the following people:

    • Dr. R. Scott Struthers Founder, Pres, Chief Executive Officer & Director(age: 63, pay: $820,330)
    • Dr. Ajay Madan DABT, Ph.D., D.A.B.T. Chief Devel. Officer(age: 57, pay: $567,530)
    • Mr. Marc J. C. Wilson Chief Financial Officer & Sec.(age: 46, pay: $527,720)
  • Is Crinetics Pharmaceuticals founder-led company?

    Yes, Crinetics Pharmaceuticals is a company led by its founder Dr. R. Scott Struthers.

  • How many employees does Crinetics Pharmaceuticals have?

    As Jul 2024, Crinetics Pharmaceuticals employs 290 workers.

  • When Crinetics Pharmaceuticals went public?

    Crinetics Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 18 Jul 2018.

  • What is Crinetics Pharmaceuticals's official website?

    The official website for Crinetics Pharmaceuticals is crinetics.com.

  • Where are Crinetics Pharmaceuticals's headquarters?

    Crinetics Pharmaceuticals is headquartered at Building No. 2, San Diego, CA.

  • How can i contact Crinetics Pharmaceuticals?

    Crinetics Pharmaceuticals's mailing address is Building No. 2, San Diego, CA and company can be reached via phone at 858 450 6464.

Crinetics Pharmaceuticals company profile:

Crinetics Pharmaceuticals, Inc.

crinetics.com
Exchange:

NASDAQ

Full time employees:

290

Industry:

Biotechnology

Sector:

Healthcare

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Building No. 2
San Diego, CA 92121

CIK: 0001658247
ISIN: US22663K1079
CUSIP: 22663K107